Acadia Pharmaceuticals Inc. (ACAD) announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints.
According to the company, neither dose of ACP-104 demonstrated improved efficacy as compared to placebo.
Uli Hacksell, Chief Executive Officer, said, "While we will thoroughly analyze the data to understand the outcome, we currently do not anticipate conducting further studies with ACP-104."
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.